(Q45257719)

English

Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study

scientific article published in March 2005

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

0 references

1 reference

based on heuristic

inferred from title

Josep Maria Haro

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

M Lambert

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

D Novick

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

E T Edgell

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

L Kennedy

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M Ratcliffe

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

D Naber

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Acta Psychiatrica Scandinavica

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

232-243

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

The impact of weight gain on quality of life among persons with schizophrenia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Weight gain from novel antipsychotic drugs: need for action

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

A review of the effect of atypical antipsychotics on weight

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Antipsychotic-induced weight gain and therapeutic response: a differential association.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00451.X

21 January 2018

Identifiers

10.1111/J.1600-0447.2004.00451.X

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45257719&oldid=2173010311"